$IQV

BOUSBIB ARI sold (to issuer) $12.2M of IQV

BOUSBIB ARI (See Remarks) sold (to issuer) 49,927 shares of IQVIA HOLDINGS INC. (IQV) at an average of $244.70 ($244.60–$247.00, $12.22M total) across 2 trades on 2026-07-29.

Original reporting
SEC EDGAR · BOUSBIB ARI
Published Jul 31, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosure provides a concrete insider activity datapoint (size, price range, and sale-to-issuer code) but does not introduce new fundamental information.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the filing does not change IQVIA’s outlook.

03

What to watch

No 10b5-1 plan is indicated, so traders may scrutinize whether the sale was discretionary versus plan-driven, though the filing still lacks any stated rationale.

Relevance 7/10Novelty 5/10Timing: filed 2026-07-31, transaction dated 2026-07-29

Background

SEC Form 4 insider transaction for IQVIA Holdings Inc., reported by officer/director BOUSBIB ARI.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer/director BOUSBIB ARI sold 49,927 shares to the issuer for about $12.22M at $244.60 to $247.00 on 2026-07-29.

Expected impact

Likely limited near-term impact; any effect is more about interpreting insider behavior than new fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with transaction size and pricing, but it does not include new company guidance, operating results, or regulatory/legal developments.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the code is sale to issuer, the transaction may reflect routine buyback participation or pre-arranged mechanics rather than a negative view on IQVIA.

Key entities

  • IQVIA HOLDINGS INC.

    Company whose insider transaction is disclosed on SEC Form 4.

  • BOUSBIB ARI

    Officer and director reporting the sale to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVMed

Stifel raises IQVIA stock price target on improving market backdrop

Stifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.

$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.